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The Incidence and Clinical Relevance
of Graft Hypertrophy After Matrix-Based
Autologous Chondrocyte Implantation
Matthias F. Pietschmann,* MD, Thomas R. Niethammer,* MD, Annie Horng,y MD,
Mehmet F. Gu¨lecyu¨z,* MD, Isa Feist-Pagenstert,* MD, Volkmar Jansson,* MD, Dipl-Ing,
and Peter E. Mu¨ller,*z MD
Investigation performed at the Department of Orthopaedic Surgery,
University Hospital of Munich (LMU), Campus Großhadern, Munich, Germany
Background: Graft hypertrophy is the most common complication of periosteal autologous chondrocyte implantation (p-ACI).
Purpose: The aim of this prospective study was to analyze the development, the incidence rate, and the persistence of graft hyper-
trophy after matrix-based autologous chondrocyte implantation (mb-ACI) in the knee joint within a 2-year postoperative course.
Study Design: Case series; Level of evidence, 4.
Methods: Between 2004 and 2007, a total of 41 patients with 44 isolated cartilage defects of the knee were treated with the mb-
ACI technique. The mean age of the patients was 35.8 years (standard deviation [SD], 11.3 years), and the mean body mass index
was 25.9 (SD, 4.2; range, 19-35.3). The cartilage defects were arthroscopically classified as Outerbridge grades III and IV. The
mean area of the cartilage defect measured 6.14 cm2 (SD, 2.3 cm2). Postoperative clinical and magnetic resonance imaging
(MRI) examinations were conducted at 3, 6, 12, and 24 months to analyze the incidence and course of the graft.
Results: Graft hypertrophy developed in 25% of the patients treated with mb-ACI within a postoperative course of 1 year; 16% of
the patients developed hypertrophy grade 2, and 9% developed hypertrophy grade 1. Graft hypertrophy occurred primarily in the
first 12 months and regressed in most cases within 2 years. The International Knee Documentation Committee (IKDC) and visual
analog scale (VAS) scores improved during the postoperative follow-up time of 2 years. There was no difference between the
clinical results regarding the IKDC and VAS pain scores and the presence of graft hypertrophy.
Conclusion: The mb-ACI technique does not lead to graft hypertrophy requiring treatment as opposed to classic p-ACI. The fre-
quency of occurrence of graft hypertrophy after p-ACI and mb-ACI is comparable. Graft hypertrophy can be considered as a tem-
porary excessive growth of regenerative cartilage tissue rather than a true graft hypertrophy. It is therefore usually not a persistent
or systematic complication in the treatment of circumscribed cartilage defects with mb-ACI.
Keywords: cartilage; autologous chondrocyte implantation; graft hypertrophy
Brittberg et al first described the classic autologous chondro-
cyte implantation (ACI) with a periosteal flap in 1994.2 Since
then, the safety and the efficiency of this method for the
treatment of large circumscribed cartilage defects in the
knee joint have been verified in numerous long-term stud-
ies.2,19,20,23 Apart from the fact that the technique of ACI is
fastidious, the main problem of the ACI was the high rate
of graft hypertrophy (GH), which was attributed primarily
to the periosteal flap cover. Graft hypertrophy is the most
common complication of the classic periosteal flap ACI
(p-ACI), with an incidence of 36%.1,3,10,12,15-17,24 This hyper-
trophy often results in clinical symptoms, thus resulting in
revision surgery with ablation of the hypertrophic cartilage.17
The matrix-based ACI (mb-ACI) is the advancement of the
classic p-ACI technique, where the chondrocytes are seeded
on an absorbable matrix. This method has the advantage of
a stable and 3-dimensional arrangement of the chondrocytes
in the cartilage defect and allows a simplification of the sur-
gical handling. The clinical results of the mb-ACI are compa-
rable with those of the classic ACI.1,4,9,17 Because the
periosteal cover of the defect is not applicable using the
mb-ACI technique, we have assumed that the rate of GH is
smaller than after p-ACI.
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The aim of this prospective study was the analysis of the
development, the incidence rate, and the persistence of GH
after mb-ACI in the knee joint in a 2-year postoperative
course. The following hypotheses were postulated: (1) The
incidence of GH after mb-ACI is lesser than that reported
for p-ACI because periosteal flap coverage is not applied. (2)
The necessity of GH treatment should therefore be distinctly
less in comparison to p-ACI. The data were retrieved by ana-
lyzing the rate of revision arthroscopy because of GH as well
as the correlation between GH and the International Knee
Documentation Committee (IKDC) score. Our results after
mb-ACI surgery were compared with the incidence rate and
clinical relevance of GH after p-ACI in the literature.
MATERIALS AND METHODS
Overview
Between 2004 and 2007, a total of 41 patients with 44 iso-
lated cartilage defects of the knee were treated with the
mb-ACI technique. The mean age of the patients was
35.8 years (standard deviation [SD], 11.3 years), with
a sex ratio of 24 men to 17 women and a mean body
mass index (BMI) of 25.9 (SD, 4.2; range, 19-35.3). The car-
tilage defects were arthroscopically classified as Outer-
bridge grades III and IV. The mean area of the cartilage
defect measured 6.14 cm2 (SD, 2.3 cm2). Cartilage defect
localizations were distributed as follows: 23 (52.3%) of
the cartilage defects treated lay femoral, and 21 (47.7%)
lay retropatellar. Excluded were patients with osteoarthro-
sis of the knee, joint instability, arthritis, corresponding
chondral defects, and more than 2 focal cartilage defects.
The following cosurgeries were performed: partial
meniscus resection (n = 4), cartilage shaving/smoothing
(n = 7), plica resection (n = 1), removal of foreign bodies
(n = 4), microfracture (n = 2), spongiosaplasty (n = 6), osteo-
chondritis dissecans (OD) refixation (n = 1), tibial tuberos-
ity transfer (n = 1), high tibial osteotomy (HTO) (n = 1),
anterior cruciate ligament (ACL) reconstruction (n = 2),
and lateral release (n = 1).
mb-ACI and Rehabilitation
The scaffolds (Novocart 3D, TETEC AG, Reutlingen, Ger-
many) were attached to healthy cartilage with an absorb-
able Vicryl USP 5-0 suture (Ethicon Inc, Johnson &
Johnson, Norderstedt, Germany). Alternatively, in 12
cases (27.3%), the scaffolds were affixed to the bone using
pins in cases where a fixation was not possible because of
a lack of healthy and stable cartilage tissue. Fibrin glue
was not used. After 24 hours of bed rest and drain removal,
postoperative after-care treatment of the femoral cartilage
defects began using a continuous passive motion (CPM)
device on the second postoperative day. With defects on
the femoral condyles, weightbearing was limited to 20 kg
for 6 weeks, while flexion was increased quickly. Patients
with patellar defects were fitted with a knee brace and
set to limited flexion of 30 for 2 to 3 weeks. Afterward,
flexion was gradually increased. Full weightbearing was
allowed with full extension.
Clinical Scores
The International Cartilage Repair Society (ICRS) Cartilage
Injury Standard Evaluation Form 2000 was used as a basis
for the assessment of subjective and objective clinical
parameters as well as the 2000 IKDC Subjective Knee Eval-
uation Form and the visual analog scale (VAS) for the reg-
istration of rest pain and pain after activity. The data
were collected preoperatively and postoperatively (after 6,
12, and 24 months), and the results were recorded in the
standardized ICRS form. The IKDC and VAS scores used
in this study are established and validated scores in the
follow-up examination of cartilage regeneration procedures
and show a high rate of reliability and reproduction,11,22
hence the frequent use of these scores in follow-up examina-
tions after p-ACI and mb-ACI.9,14,17,18,21
Magnetic Resonance Imaging
A follow-up magnetic resonance imaging (MRI) examina-
tion was performed after 3, 6, 12, and 24 months using
a 1.5-T machine (Magnetom Sonata, Fa Siemens AG,
Erlangen, Germany) with the use of a commercially avail-
able circular polarizing 1-channel knee spool in a predeter-
mined protocol. Fast spin echo (dual T2-FSE) and fat
saturation gradient echo (3D-GE-FS) sequences were pro-
duced. Additionally, proton-weighted sequences as well
as T1-weighted fast low angle shot sequence (FLASH)
with selective water stimulation was performed. The 3D
FLASH sequence is a validated sequence for the measure-
ment of knee cartilage with MRI, as demonstrated by Eck-
stein et al.7 These sequences are the same ones as
described by Kreuz et al12 in the evaluation of GH after
classic ACI. Graft hypertrophy classification was rated
using the scale of Kreuz et al12 (grade 1 hypertrophy,
\125%; grade 2 hypertrophy, \150%; grade 3 hypertro-
phy,\200%; grade 4 hypertrophy, .200%).
The measurements of the cartilage thickness were done
in a blinded fashion by an experienced orthopaedic surgeon
and a radiologist who specialized in musculoskeletal radiol-
ogy. The cartilage and transplant thickness was measured
and evaluated in a standardized manner with the software
MagicView 1000VB33a/MagicWeb (Fa Siemens Medical
Systems, Erlangen, Germany) using DICOM data sets (Dig-
ital Imaging and Communications in Medicine, Rosslyn,
Virginia). Cartilage defects lying in the condylar region
were evaluated using the sagittal planes and retropatellar
defects using the axial planes. The thickest area of the graft
was measured as well as 3 regions in the adjacent normal
cartilage (Figure 1). The standardized graft and healthy car-
tilage measurements were conducted by determining the
mean values of 3 measuring points in the thickest region
of the tissue. The ratio between the thickness of the graft
and the thickness of the healthy cartilage was determined.
Statistics
The retrieved data were analyzed using the statistics pro-
gram SPSS (Statistical Package of Social Sciences, Version
18, Chicago, Illinois). The descriptive data were presented
Vol. 40, No. 1, 2012 Graft Hypertrophy After Matrix-Based ACI 69
 at LMU Muenchen on June 13, 2013ajs.sagepub.comDownloaded from 
with absolute and relative frequency of occurrence, mean
value, and standard deviation. The coherence between
GH and potential influencing factors to the various fol-
low-up examinations was verified with multiple logistic
regression analysis. Significant differences between preop-
erative and postoperative examination times were deter-
mined using the Wilcoxon test for dependent samples
and the Mann-Whitney U test for independent samples
in the comparison of 2 groups at a certain time period.
The results were significant if P\ .05.
RESULTS
Overview of the Clinical Scores
The patients from our collective showed a significantly
higher IKDC score postoperatively after 6, 12, and 24
months compared with the preoperative values. The preop-
erative IKDC value was 28.2% (SD, 18.0%). During the
postoperative observation period of 2 years, the mean
IKDC value increased to 68.6% (SD, 21.8%), with the
greatest significance at 6 and 12 months postoperatively;
a positive trend (P = .067) was observed between the values
of the 12th and 24th months (Figure 2).
Revision
Surgical revision was performed in 8 patients (19.4%). In 5
cases (11.9%), revision was necessary because of arthrofib-
rosis and in 1 case because of pain without GH, and in 2
cases, another mb-ACI was performed because of graft fail-
ure (one because of an early infection). Surgical revisions
because of GH were not performed.
Graft Hypertrophy
Eleven patients showed GH postoperatively in our patient
collective with a total sum of 44 cartilage defects (Table 1).
The GH observed occurred during the first 12 postoperative
months. In 8 patients, GH occurred after 6 months, and in
2 patients with femoral cartilage defects, GH was observed
after 12 months. No new cases of GH were observed in the
follow-up examination after 24 months (Figure 3).
Four patients developed GH grade 1 postoperatively. In
2 patients, GH grade 1 occurred after 3 months, in 2
patients after 6 months, and in 1 patient after 12 months.
In all patients with GH grade 1 (100%), a complete GH
regression was observed after 24 months.
Graft hypertrophy grade 2 occurred in 7 cases. One
patient developed GH grade 2 after 3 months, 5 patients
after 6 months, and only 1 patient after 12 months postop-
eratively. In 1 patient, the GH progressed from grade 1 to
grade 2 in a time span of 12 months. In 4 patients, a grade
2 GH persisted in the time span of 2 years. In the other 3
patients, a total regression of a grade 2 GH could be
observed (Table 2).
Localization
Cartilage defect localizations were distributed as follows:
23 (52.3%) of the cartilage defects treated were femoral,
and 21 (47.7%) were retropatellar. Femoral cartilage dam-
age occurred predominantly on the medial femoral condyle
(n = 19), and the other 4 occurred in the lateral femoral
condyle. In 3 patients, mb-ACI treatment was performed
on 2 cartilage defects lying femoral and retropatellar.
Figure 1. T1-weighted magnetic resonance imaging study of
a fast low angle shot sequence (FLASH) of a right knee after
12 months. ‘‘mb-ACI’’ shows the 3 measuring points of the
hypertrophic graft. ‘‘Cartilage’’ shows the 3 measuring points
of the normal cartilage.
Figure 2. Overview of the clinical International Knee Docu-
mentation Committee (IKDC) values with significant improve-
ment after 6, 12, and 24 months in comparison with the
preoperative results ([1] P = .001, [2] P = .001, [3] P = .001,
and [4] P = .001). The IKDC result between the 12th and
24th months was not significant using the Wilcoxon test ([5]
P = .067).
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The femoral cartilage defect size was 6.0 cm2 (SD, 2.2 cm2)
and retropatellar was 6.3 cm2 (SD, 2.5 cm2), being almost
equivalent (P = .981). There was no relevant difference
regarding the BMI and the age of the patient (Table 3).
The frequency of occurrence of GH in the femur and retro-
patellar was equivalent in all follow-up periods. In patients
with retropatellar cartilage damage, 4 cases of GH were
observed, where 3 patients developed GH grade 2 and 1
patient developed GH grade 1. Four patients developed fem-
oral GH grade 2, and 3 patients developed femoral GH grade
1. The differences regarding the frequency of various grades
of hypertrophy between the femoral and retropatellar local-
izations were statistically not significant (P = .489).
Correlation Between GH With the IKDC and VAS
During the postoperative follow-up examinations, there
was no difference between the clinical results regarding
the IKDC score and VAS pain and the presence of
GH. Patients with GH grade 1 or 2 averaged a mean
IKDC value of 57.0% (SD, 21.2%) after 12 months and
65.7% (SD, 23.9%) after 24 months. Patients without
hypertrophy presented a mean IKDC value of 62.7%
(SD, 19.2%) after 12 months and 67.7% (SD, 19.1%) after
24 months. No significant differences could be observed in
the IKDC and VAS scores in patients with GH grade 1
or 2 (P = .22 after 12 months; P = .803 after 24 months)
(Figure 4).
DISCUSSION
Graft hypertrophy is one of the most common complications
of p-ACI, with an incidence of 36%,1,3,10,12,15-17,24 and leads
to clinical discomfort as well as surgical revision with abra-
sion of the hypertrophy.17 The periosteal flap cover was




Grade 0 (No Hypertrophy) Grade 1 (100%-125%) Grade 2 (125%-150%)
3 months
Defects, n (%) 37 (84.1) 2 (4.5) 1 (2.3)
Age, mean (range), y 35.1 (16-50) 45.5 (43-48) 16
Location, n (%)
Medial femoral condyle 16 (43.2) 1 (50) 0
Lateral femoral condyle 3 (8.1) 0 1 (100)
Retropatellar 18 (48.6) 1 (50) 0
Surgical intervention 0 0 0
6 months
Defects, n (%) 34 (77.3) 2 (4.5) 6 (13.6)
Age, mean (range), y 36.2 (16-50) 25 (17-33) 32.5 (16-46)
Location, n (%)
Medial femoral condyle 14 (41.2) 2 (100) 1 (16.7)
Lateral femoral condyle 2 (5.9) 0 2 (33.3)
Retropatellar 18 (52.9) 0 3 (50)
IKDC score, % / average VAS score 50.9%/4.4 58.9%/2.5 48.7%/4.3
Surgical intervention 0 0 0
12 months
Defects, n (%) 30 (83.3) 2 (5.6) 4 (11.1)
Age, mean (range), y 35.9 (16-50) 47 26.3 (16-46)
Location, n (%)
Medial femoral condyle 14 (46.7) 1 (50) 0
Lateral femoral condyle 1 (3.3) 0 2 (50)
Retropatellar 15 (50) 1 (50) 2 (50)
IKDC score, % / average VAS score 62.7%/3.3 33.7%/5.0 52.5%/4.5
Surgical intervention 0 0 0
24 months
Defects, n (%) 29 (87.9) 0 4 (12.1)
Age, mean (range), y 36.1 (16-49) 43 26.3 (16-46)
Location, n (%)
Medial femoral condyle 13 (44.8) 0 0
Lateral femoral condyle 1 (3.4) 0 2 (50)
Retropatellar 15 (51.7) 0 2 (50)
IKDC score, % / average VAS score 67.7%/3.3 0 68.7%/4.1
Surgical intervention 0 0 0
aInternational Knee Documentation Committee (IKDC); VAS, visual analog scale.
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occurrence of GH using the mb-ACI method and its clinical
relevance are still uncertain.
Up to now, GH after mb-ACI was only descriptively ana-
lyzed according to its macroscopic appearance in arthros-
copy or in MRI examinations.1,17 Therefore, a comparison
between these observations and results of studies using
different methods is either insufficient or not possible.
Kreuz et al12 were the first to establish a GH classification
with the use of MRI examinations and classified the GH in
4 grades. This form of classification was only performed in
the classic ACI using periosteal flap plastic, and therefore,
no results existed for the GH after mb-ACI.
This study closes the gap by revealing data regarding
the GH after mb-ACI and its influence on the clinical
results. The thickness of the graft as well as the thickness
of the adjacent healthy cartilage was determined by means
TABLE 2
Postoperative Course of Graft Hypertrophy
Graft Hypertrophy Grade
Patient Gender Age, y Defect Localization After 3 Months After 6 Months After 12 Months After 24 Months
1 Female 17 Femoral 0 1 0 0
9 Male 16 Femoral 2 2 2 2
10 Male 33 Femoral 0 1 0 0
16 Female 46 Retropatellar 0 2 2 2
17 Female 46 Femoral 0 0 1 0
21 Male 43 Femoral 1 2 0 0
22 Male 24 Femoral 0 0 2 2
24 Male 46 Retropatellar 0 2 0 0
28 Male 25 Femoral 0 2 0 0
34 Female 19 Retropatellar 0 2 2 2
40 Female 48 Retropatellar 1 0 1 0
TABLE 3
Overview of the Localization of Graft Hypertrophy
Femoral Retropatellar
No. (%) 24 (54.5) 20 (45.5)
Body mass index, mean 6 standard deviation (range) 25.9 6 4.1 (19-34) 26 6 4.5 (19.2-35.3)
Age, mean 6 standard deviation (range), y 36.4 6 12.0 (16-50) 35 6 11.0 (16-49)
Defect size, mean 6 standard deviation (range), cm2 6.0 6 2.2 (2-10) 6.3 6 2.5 (4-12)
Figure 4. Clinical International Knee Documentation Com-
mittee (IKDC) results after 2 years in patients with graft hyper-
trophy grades 1 and 2. The difference between the clinical
















6 months 12 months 24 months
GH grade 1
GH grade 1 new
GH grade 2
GH grade 2 new
Figure 3. Occurrence of graft hypertrophy (GH). The GH
occurred during the first 12 postoperative months. No new
cases of GH could be observed in the follow-up examination
after 24 months.
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of postoperative MRI examinations at regular intervals,
and its course was observed. The ratio between the thick-
ness of the graft and the thickness of the healthy cartilage
was determined and could now classify the GH. The stan-
dardized graft and healthy cartilage measurements were
conducted by determining the mean values of 3 measuring
points in the thickest region of the tissue. The MRI
sequence for determining the cartilage thickness of the
knee joint is an established method.5-7
The aim of this study was to analyze the occurrence of
hypertrophic cartilage growth in the knee joint after mb-
ACI and its postoperative course in 2 years. The following
hypotheses could be answered:
 Hypertrophy as a complication after mb-ACI treat-
ment of circumscribed cartilage defects occurs in
25%, as frequently as reported in classic p-ACI (9%-
40%).1,15,20
 The occurrence of GH in the postoperative course
after mb-ACI in the knee joint is evident after the
first 12 months and in 75% of the cases within the
first 6 months.
 Graft hypertrophy after mb-ACI treatment cannot be
regarded as a complication because it does not lead to
poorer clinical results in IKDC and VAS scores in
a postoperative phase of 2 years. In our study, a
second-look arthroscopy for the treatment of GH
was not necessary.
 The patients in our collective showed significant
improvement of the IKDC and VAS scores during
the postoperative follow-up time span of 2 years.
The improvement was significantly better compared
with the preoperative results after 6, 12, and 24
months. A significant improvement of the IKDC score
was evident between the 6th and 12th months. A pos-
itive, although insignificant, trend was observed
between the 12th and 24th months.
 Graft hypertrophy after classic p-ACI was attributed
to the periosteal flap. Based on this theory, a lower
incidence of GH after mb-ACI would have been antic-
ipated because a periosteal flap was not used, but this
was not the case in this study. With a 25% incidence
rate in our study, the rate of GH is similar to that of
the classic p-ACI. One must therefore conclude that
transplanted chondrocytes also have hypertrophy
potential.13 Nevertheless, we could not determine
a correlation between the occurrence of GH and infe-
rior clinical values in the IKDC or the VAS scores. It
must therefore be clarified after which period of carti-
lage growth GH is to be considered a complication.
The lack of GH grades 3 and 4 in our study supports
the thesis that a temporary GH is to be regarded as
an accommodation reaction and not a complication
requiring treatment.
Graft Hypertrophy Occurs in the First 12 Months
and Regresses in Most Cases Within 2 Years
Graft hypertrophy developed in 25% of the patients treated
with mb-ACI within a postoperative course of 1 year.
Sixteen percent of the patients developed hypertrophy
grade 2, and 9% developed hypertrophy grade 1. These
results are comparable to the frequency of occurrence of
GH after classic p-ACI in the literature.1,8,9 However,
a direct comparison of the results from this study and
the results from Kreuz et al12 shows that the grades of
GH are certainly lower and that no severe cases of GH
such as grade 3 or 4 are observed. This explains why no
patient in our study required revision surgery because of
GH. All grade 1 GH cases in the series of Kreuz et al12
did not require surgery as well. The lack of GH grades 3
and 4 in our examination supports the thesis that a tempo-
rary GH is more an accommodation reaction than a compli-
cation requiring treatment.
All the GHs in this study developed within 12 months
postoperatively and in 75% of the cases within the first 6
months. A recurrence of GH in the second postoperative
year could not be determined. All grade 1 GHs regressed
within the second postoperative year. A progression to
a grade 2 GH was observed in only one case. In patients
who developed a grade 2 GH, the hypertrophy persisted
within the 24-month postoperative phase without having
a negative influence on the clinical outcome. In only 43%
of the cases, a total regression after 2 years could be
documented.
The majority of grade 1 GH cases can be considered
‘‘temporary’’ GH because these develop within the first
year after implantation and are regressive in the course
of the examination period. One can assume that the exces-
sive growth of newly developing cartilage tissue comes to
a standstill and even undergoes partial regression due to
the biomechanical strain on it. After the development of
grade 2 GH, a total adjustment of the new cartilage to
the circumjacent level could be examined in less than
50% of the cases. Nevertheless, a correlation with this
observation and poor clinical results could not be associ-
ated. In this case, with a persistence of the GH grade 2
after 24 months, it is possible that symptoms would arise.
Localization of Cartilage Damage
Has No Influence on GH
There are contradictory propositions regarding classic
p-ACI with periosteal flap and the occurrence of retropatel-
lar GH in the literature.2,12 In our study, a significantly
higher occurrence of retropatellar GH could not be found.
We rather saw the statistically insignificant tendency of
more femoral GHs.
CONCLUSION
Matrix-based ACI does not lead to GH that requires treat-
ment, as opposed to classic p-ACI of the knee joint. The fre-
quency of occurrence of GH after p-ACI and mb-ACI is
comparable. Nevertheless, with the mb-ACI method, only
mild forms of GH classified as grades 1 and 2 were to be
observed. Graft hypertrophy after mb-ACI occurs within
the first postoperative year, and within the second year,
all grade 1 GHs regenerated completely. This can therefore
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be considered as a temporary excessive growth of regener-
ative cartilage tissue rather than a true GH. Grade 2 GHs
persist in size in more than half of the cases after 2 years
but do not progress. There was no negative influence of
GH grades 1 and 2 on the clinical results in the IKDC
and VAS pain scores during the 2-year postoperative
time period. A correlation between the higher rate of GH
to a certain localization of the grafts (femoral vs retropatel-
lar) could not be verified. It seems that GH is therefore not
a relevant complication in the treatment of circumscribed
cartilage defects with mb-ACI.
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